Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sitagliptin · 1 trial · 1 indication
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change.
| Arm | Type | Description |
|---|---|---|
| Canagliflozin 300 mg | EXPERIMENTAL | Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea |
| Sitagliptin 100 mg | ACTIVE_COMPARATOR | Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea |
| Name | Type | Description |
|---|---|---|
| Sitagliptin 100 mg | DRUG | One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea |
| Canagliflozin 300 mg | DRUG | One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea |
| Metformin | DRUG | Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study. |
| Sulphonylurea | DRUG | Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study. |
Inclusion Criteria: * All patients must have a diagnosis of T2DM and be currently treated with metformin and sulphonylurea * Patients in the study must have a HbA1c between \>=7 and \<=10.5% and a fasting plasma glucose (FPG) \<300 mg/dL (16.7 mmol/L) Exclusion Criteria: * History of diabetic ket...
Sitagliptin is used for the treatment of Diabetes Mellitus, Type 2. It is a small molecule being developed by Johnson & Johnson for this metabolic condition. The drug is currently in Phase 3 clinical development, meaning it is investigational and not yet approved for use.
Sitagliptin is a small molecule being studied for the treatment of Type 2 Diabetes Mellitus. Its specific molecular target has not been disclosed in the available information. The drug is currently in Phase 3 clinical trials, indicating it is still under investigation.
Sitagliptin is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker JNJ. The drug is a small molecule intended for the treatment of Type 2 Diabetes Mellitus and is currently in Phase 3 clinical development.
Sitagliptin is in Phase 3 clinical development. It is an investigational drug for the treatment of Type 2 Diabetes Mellitus and has not yet been approved by regulatory authorities. The drug is being developed by Johnson & Johnson.
Sitagliptin has been studied in a Phase 3 clinical trial with the identifier NCT01137812, titled 'The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)'. This trial, which has been completed, enrolled 756 participants with Type 2 Diabetes Mellitus.
No, Sitagliptin is not the same as canagliflozin. The clinical trial NCT01137812, which studied Sitagliptin, was a comparator trial that included canagliflozin as an active control. Sitagliptin is a separate drug being developed by Johnson & Johnson for Type 2 Diabetes Mellitus.